The pharmacological studies performed on non human primates (NHP) generate complementary data that bridge translational research from small animal models to humans. They constitute an essential step for the preclinical development of drug candidates.
The relevance of our translational models in the NHP makes them predictive enough to succeed:
- Pharmacokinetics (PK) and toxicity studies. These exploratory studies produce a complete dataset describing the in vivo behaviour of drug candidates ahead of preclinical regulatory studies. Derisking novel drugs and immunotherapies, particularly in the early stages, further increases the drug candidates’ development success into the clinics. More information
- Proof of Concept studies (POC) with proprietary and predictive physiopathological models providing decisive evidence of drug candidates’ efficacy. More information
- Regulatory GLP studies necessary for the drug submission to regulatory agencies. More information
Cynbiose is eligible for the French Research Tax Credit (CIR). The agreement is delivered by the French Ministry of Higher Education and Research.
CIR is a tax measure designed to support the R&D expenditures of companies located in France.
It is calculated on the basis of R&D expenditures – including those subcontracted to approved outsourced research service providers.